JCR Pharma, The Current Fiscal Year Ordinary Profit Revised Downward to a Loss

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Mar 27, 2025 4:00 pm JST Revision

4552 JCR Pharmaceuticals Co.,Ltd. 【J-GAAP】

Guidance Update Report

JCR Pharmaceuticals Co.,Ltd. <4552> [TSE Prime] announced a performance revision after the market closed on March 27th (16:00). The consolidated ordinary profit/loss for the fiscal year ending March 2025 has been revised downward from an expected profit of 0.75 billion yen to a loss of 6.7 billion yen (compared to a profit of 7.26 billion yen in the previous period), turning to a loss outlook.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated ordinary profit/loss has been revised downward from an expected profit of 2.37 billion yen to a loss of 5.07 billion yen (compared to a profit of 0.13 billion yen in the same period of the previous year), turning to a loss outlook.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	22,343	2,139	2,371	2,891	23.7	10	Jan 31, 2025	J-GAAP
Oct - Mar, 2024 New	16,343	-5,261	-5,079	-3,609	-29.2	10	Mar 27, 2025	J-GAAP
Revision Rate	-26.9%	－	－	－	－

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	39,000	1,400	750	2,200	18.1	20	Jan 31, 2025	J-GAAP
Mar, 2025 New	33,000	-6,000	-6,700	-4,300	-34.7	20	Mar 27, 2025	J-GAAP
Revision Rate	-15.4%	－	－	－	－

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	18,599	633	138	254	2.0	10	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	16,343	-5,261	-5,079	-3,609	-29.2	10	Mar 27, 2025	J-GAAP
YoY	-12.1%	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	34,343	4,975	5,418	3,772	30.4	20	May 11, 2023	J-GAAP
Mar, 2024	42,871	7,531	7,264	5,507	44.1	20	May 10, 2024	J-GAAP
Mar, 2025 Guidance	33,000	-6,000	-6,700	-4,300	-34.7	20	Mar 27, 2025	J-GAAP
YoY	-23.0%	－	－	－	－